The Federal Circuit affirmed a ruling by the US International Trade Commission that Wuhan Healthgen's importation of recombinant human serum albumin (rHSA) violated Ventria Bioscience's patent. Ventria, a small Kansas biotech firm, produces rHSA from genetically modified plants, which offers advantages over traditional animal-sourced albumin. Ventria sought a trade exclusion order, which was largely granted, showcasing the importance of Section 337 in supporting domestic innovation. The case highlights how patent protection can aid small U.S. businesses in the biotech sector against foreign competition.
The Federal Circuit upheld the ITC's ruling that Wuhan Healthgen infringed Ventria's patent regarding recombinant human serum albumin, emphasizing the patent's unique production method.
Ventria, a small biotech firm, innovates by creating rHSA from genetically modified plants, offering significant advantages over traditional animal-derived sources for laboratory cell cultures.
Under Section 337, a domestic industry must show substantial U.S. investment related to the patented technology, ensuring protection for small, innovative U.S. companies.
Ventria successfully argued for a trade exclusion order against Wuhan Healthgen, demonstrating the importance of patent law in supporting innovation in biotechnology.
Collection
[
|
...
]